These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11775420)

  • 41. Carvedilol versus metoprolol in the acute phase of myocardial infarction:
    Bonnemeier H; Ortak J; Tölg R; Witt M; Schmidt J; Wiegand UK; Bode F; Schunkert H; Richardt G
    Pacing Clin Electrophysiol; 2005 Jan; 28 Suppl 1():S222-6. PubMed ID: 15683501
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The influence of carvedilol on atrial connexin 40 after myocardial infarction.
    Cao F; Huang C; Jiang H; Li X; Bao M; Tang Y
    Acta Cardiol; 2008 Jun; 63(3):303-8. PubMed ID: 18664019
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Three decades of clinical trials with beta-blockers: the contribution of the CAPRICORN trial and the effect of carvedilol on serious arrhythmias.
    Pratt CM
    J Am Coll Cardiol; 2005 Feb; 45(4):531-2. PubMed ID: 15708699
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical trials of newly developed anti-cancer agents in children with acute leukemia.
    Singh TP
    Contemp Clin Trials; 2006 Dec; 27(6):493. PubMed ID: 17056299
    [No Abstract]   [Full Text] [Related]  

  • 45. [Comet or snoop?].
    Heinzl S
    Med Monatsschr Pharm; 2003 Sep; 26(9):299. PubMed ID: 14526612
    [No Abstract]   [Full Text] [Related]  

  • 46. Role of carvedilol in atrial fibrillation: insights from clinical trials.
    Gheorghiade M; Lukas MA
    Am J Cardiol; 2004 May; 93(9A):53B-7B. PubMed ID: 15144939
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Landmark studies: the Australia/New Zealand Heart Failure Collaborative Group (ANZ) Trial and the US Carvedilol Trials Program.
    Gilbert EM
    Am J Cardiol; 2004 May; 93(9A):30B-4B. PubMed ID: 15144934
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [A fairer comparison between carvedilol and metoprolol is still to be done].
    Johnsson G; Aberg J
    Lakartidningen; 2003 Oct; 100(44):3543-4, 3544-5. PubMed ID: 14651018
    [No Abstract]   [Full Text] [Related]  

  • 49. Switching to once-daily evidence-based [beta]-blockers in patients with systolic heart failure or left ventricular dysfunction after myocardial infarction.
    Albert NM
    Crit Care Nurse; 2007 Dec; 27(6):62-72. PubMed ID: 18032686
    [No Abstract]   [Full Text] [Related]  

  • 50. The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients.
    Goldhammer E; Maor I; Shnitzer S; Lanir A; Abinader EG
    J Cardiovasc Med (Hagerstown); 2007 Jun; 8(6):453-6. PubMed ID: 17502762
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Carvedilol versus metoprolol in patients undergoing direct percutaneous coronary interventions for myocardial infarction: effects on QT dynamicity.
    Bonnemeier H; Ortak J; Tölg R; Witt M; Schmidt J; Wiegand UK; Bode F; Schunkert H; Richardt G
    Pacing Clin Electrophysiol; 2005 Jan; 28 Suppl 1():S217-21. PubMed ID: 15683500
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol in severe heart failure.
    Fowler MB
    Am J Cardiol; 2004 May; 93(9A):35B-9B. PubMed ID: 15144935
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Effects of carvedilol on the expression of IL-1beta and collagen precipitation in myocardium in post-myocardial infarction rats ].
    Li B; Liao YH; Cheng Q; Ge HX; Guo ZQ; Lu BJ
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(6):416-8. PubMed ID: 15854535
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.
    Louis A; Cleland JG; Crabbe S; Ford S; Thackray S; Houghton T; Clark A
    Eur J Heart Fail; 2001 Jun; 3(3):381-7. PubMed ID: 11378012
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003.
    Fleming T; Borer J; Armstrong PW; Pfeffer M;
    Circulation; 2003 Jan; 107(2):e9002-3. PubMed ID: 12538443
    [No Abstract]   [Full Text] [Related]  

  • 56. COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure.
    Greenberg BH; Mehra M; Teerlink JR; Ordronneau P; McCollum D; Gilbert EM
    Am J Cardiol; 2006 Oct; 98(7A):53L-59L. PubMed ID: 17023233
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Major heart failure news from 2001.
    Francis D
    Heart Fail Monit; 2002; 2(4):147-8. PubMed ID: 12638556
    [No Abstract]   [Full Text] [Related]  

  • 58. Beta-blockers for the post-myocardial infarction patient: current clinical evidence and practical considerations.
    Fonarow GC
    Rev Cardiovasc Med; 2006; 7(1):1-9. PubMed ID: 16534490
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis.
    Packer M; Antonopoulos GV; Berlin JA; Chittams J; Konstam MA; Udelson JE
    Am Heart J; 2001 Jun; 141(6):899-907. PubMed ID: 11376302
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Value of beta-blocker therapy in treatment of coronary heart disease and sudden cardiac death with special reference to carvedilol].
    Zehender M; Just H
    Z Kardiol; 1996; 85 Suppl 7():23-9. PubMed ID: 9082680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.